Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.46
EPS est.
$-0.50
EPS surprise
+8.18%
1-day move
-3.81%
Edgewise Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the lack of revenue and guidance may have contributed to the stock's decline of 3.81%. Investors will likely be looking for more information in future reports to assess the company's trajectory.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | $-0.48 | +8.18% |
| Revenue | $0M | $0M | — |
No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.
Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious diseases. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as new treatments and technologies emerge.
Last quarter
In the last quarter, Edgewise reported an EPS of $-0.47, which was worse than the expected $-0.43. The stock reacted negatively, dropping 1.53% the following day.
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
+1.49%
Avg 1-day reaction
-2.11%
Analysts expect Edgewise to report a loss of $-0.48 per share this quarter, with no revenue projected. Investors are keen to see if the company can narrow its losses or provide positive guidance.
Bull case
If Edgewise can beat earnings expectations and provide positive commentary on future drug development, it could boost investor confidence and drive the stock higher.
Bear case
Conversely, if the company misses expectations again or provides no clear path to revenue generation, it could lead to further declines in the stock price.
Key metrics to watch
EPS
$-0.48Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.
Revenue
$0MWhile no revenue is expected this quarter, any commentary on future revenue generation will be crucial for investor confidence.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-0.48?
A smaller loss than expected could indicate improving operational efficiency and boost investor sentiment.
Q2
What is the company's outlook for future revenue generation?
Any guidance on potential revenue streams will be critical for assessing the company's growth prospects.
—
Est. EPS
$0.67
Est. Rev
$390M
Impl. Move
±4.5%
Why consensus could be wrong
The Street is overly pessimistic, expecting a loss of $-0.48, but the company's recent trend of narrowing losses suggests it could outperform this expectation.
Supporting evidence
Edgewise has consistently surprised on the upside in 75% of the last eight quarters.
The options market is pricing a larger move than historically realized, indicating potential for a surprise.
Key risk
If the EPS comes in better than $-0.48, it could shift the narrative significantly.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on whether Edgewise can show signs of narrowing losses and provide a clearer path to revenue.
Bull confirmed if
A reported EPS loss of less than $-0.48 would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-0.48 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±12.71%
Historical Avg
±2.4%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±10.3% while EWTX has averaged ±2.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
67.8%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 4 of 11 (36%)
This setup has occurred 30 times across Health Care in the last 2 years. 7 of 11 (64%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.5%, with a raw directional average of +3.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
111.68%
of float
Insider
0.49%
of float
Holders
321
institutions
Top Holders· as of Jun 2026
Orbimed Advisors LLC.
15,518,492 sh · $614.1M
14.29%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Edgewise beats expectations, history suggests a potential average one-day move of +1.69%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty around future guidance.
Miss
Should the company miss expectations, history suggests an average one-day move of -1.99%, indicating a negative market reaction.
The lines on the call that would change the story.
Paradigm Biocapital Advisors LP
10,215,455 sh · $404.2M
9.41%
38.7%
RA Capital Management, L.P.
8,392,730 sh · $332.1M
7.73%
-19.5%
Blackrock Inc.
6,606,336 sh · $261.4M
6.08%
2.1%
Jupiter Topco LLC
6,075,331 sh · $240.4M
5.59%
100.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.